MENU
+Compare
LXRX
Stock ticker: NASDAQ
AS OF
May 14 closing price
Price
$0.53
Change
-$0.10 (-15.87%)
Capitalization
193.17M

LXRX Lexicon Pharmaceuticals Forecast, Technical & Fundamental Analysis

Lexicon Pharmaceuticals Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for LXRX with price predictions
May 13, 2025

Momentum Indicator for LXRX turns negative, indicating new downward trend

LXRX saw its Momentum Indicator move below the 0 level on May 08, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In of the 95 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LXRX moved out of overbought territory on May 02, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for LXRX turned negative on May 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

LXRX moved above its 50-day moving average on April 21, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LXRX crossed bullishly above the 50-day moving average on April 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LXRX advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .

LXRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 133 cases where LXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.324) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (5.476) is also within normal values, averaging (254.920).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

LXRX is expected to report earnings to rise 31.43% to -9 cents per share on July 31

Lexicon Pharmaceuticals LXRX Stock Earnings Reports
Q2'25
Est.
$-0.09
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.03
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.01
The last earnings report on May 13 showed earnings per share of -7 cents, beating the estimate of -11 cents. With 6.07M shares outstanding, the current market capitalization sits at 193.17M.
A.I. Advisor
published General Information

General Information

a company, which engages in discovery and development of breakthrough treatments for human disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2445 Technology Forest Boulevard
Phone
+1 281 863-3000
Employees
285
Web
https://www.lexpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSACX18.19N/A
N/A
Morgan Stanley Inst Passport ovrs eq I
NCGFX63.23N/A
N/A
New Covenant Growth
HTECX23.14N/A
N/A
Hennessy Technology Investor
FGFRX40.95N/A
N/A
Federated Hermes Intl Leaders R
HGOVX72.97N/A
N/A
Hartford Growth Opportunities R6

LXRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-15.57%
PLRX - LXRX
42%
Loosely correlated
-1.45%
OCUL - LXRX
39%
Loosely correlated
-1.00%
ABOS - LXRX
38%
Loosely correlated
-6.67%
VCYT - LXRX
37%
Loosely correlated
-2.80%
AURA - LXRX
35%
Loosely correlated
-6.84%
More